Chengdu Kanghong Pharmaceuticals Group Co Ltd - Asset Resilience Ratio
Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) has an Asset Resilience Ratio of 25.99% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 002773 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2022)
This chart shows how Chengdu Kanghong Pharmaceuticals Group Co Ltd's Asset Resilience Ratio has changed over time. See 002773 total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Chengdu Kanghong Pharmaceuticals Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Chengdu Kanghong Pharmaceuticals Group C stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.56 Billion | 25.99% |
| Total Liquid Assets | CN¥2.56 Billion | 25.99% |
Asset Resilience Insights
- Very High Liquidity: Chengdu Kanghong Pharmaceuticals Group Co Ltd maintains exceptional liquid asset reserves at 25.99% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Chengdu Kanghong Pharmaceuticals Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Chengdu Kanghong Pharmaceuticals Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Chengdu Kanghong Pharmaceuticals Group Co Ltd (2015–2022)
The table below shows the annual Asset Resilience Ratio data for Chengdu Kanghong Pharmaceuticals Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 1.30% | CN¥100.00 Million ≈ $14.63 Million |
CN¥7.72 Billion ≈ $1.13 Billion |
-1.58pp |
| 2021-12-31 | 2.88% | CN¥200.00 Million ≈ $29.27 Million |
CN¥6.96 Billion ≈ $1.02 Billion |
-1.21pp |
| 2018-12-31 | 4.08% | CN¥212.00 Million ≈ $31.02 Million |
CN¥5.19 Billion ≈ $760.17 Million |
-2.84pp |
| 2016-12-31 | 6.92% | CN¥260.00 Million ≈ $38.05 Million |
CN¥3.76 Billion ≈ $549.94 Million |
-0.32pp |
| 2015-12-31 | 7.24% | CN¥210.00 Million ≈ $30.73 Million |
CN¥2.90 Billion ≈ $424.54 Million |
-- |
About Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chengdu Kanghong Pharmaceutical Group Co., Ltd engages in the research, development, manufacture, and distribution of medicine for ophthalmic, neuropsychiatric and other applications in China. It also develops a pipeline of clinical and pre-clinical programs for ophthalmology, CNS, oncology, and common disease. The company was founded in 1996 and is based in Chengdu, China.